Avistone Biotechnology receives NMPA approval for Vebreltinib in China
Avistone Biotechnology Co. Ltd., a precision oncology therapeutics company, has announced the conditional approval from the National Medical Products Administration (NMPA) of China for commercializing Vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Pivotal Phase II Study Results Underpinning Approval The NMPA’s decision was influenced by the positive outcomes […]